Search results
For the journal "Vaccine"Search results
For the journal "Vaccine"
Chikungunya
Chikungunya virus virus-like particle vaccine (Vimkunya) induces a rapid and durable antigen-specific CD4+ T cell response
Chikungunya virus (CHIKV), a single-stranded, positive-sense RNA alphavirus, is transmitted to humans by infected Aedes mosquitoes. It poses an emerging threat to public health in Aedes-endemic countries and a growing risk to travelers visiting these countries. Typical acute symptoms include fever, arthralgia,...
Tick Borne Encephalitis (TBE)
Tick-borne encephalitis vaccination coverage among outdoor workers in Sweden: a nationwide survey
Tick-borne encephalitis (TBE) is an emerging public health concern in Sweden, with a steadily increasing incidence over the past two decades. Climate change, expanding tick populations, and increased human exposure contribute to the growing burden of disease. Although TBE vaccination is highly effective,...
Rabies
Factors influencing rabies vaccines immunogenicity during post-exposure prophylaxis: a systematic literature search and meta-analysis
Rabies post-exposure prophylaxis (PEP) requires timely appropriate wound management and vaccination (including concomitant rabies immunoglobulin [RIG], depending on vaccination history and wound severity) to ensure rapid increases in rabies virus neutralizing antibody (RVNA) titers, a surrogate marker...
Diphtheria
Reassurance of population immunity to diphtheria in England: Results from a 2021 national serosurvey
Diphtheria is rare in England because of an effective national immunisation schedule that includes 5 doses of a diphtheria-containing vaccine at 2, 3, 4 months, preschool and adolescent boosters. However, in recent years there has been a notable increase in cases due to Corynebacterium ulcerans...
Chikungunya
Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya
Infections with the chikungunya virus are increasingly reported due to many reasons including climate change. Two vaccines against chikungunya have recently been approved in Europe, the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya. However, no systematic review...
